Syros Pharmaceuticals Inc (SYRS)
4.97
-0.18
(-3.50%)
USD |
NASDAQ |
May 24, 16:00
4.97
0.00 (0.00%)
After-Hours: 20:00
Syros Pharmaceuticals Research and Development Expense (Quarterly): 24.66M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 24.66M |
| December 31, 2023 | 21.50M |
| September 30, 2023 | 28.28M |
| June 30, 2023 | 29.61M |
| March 31, 2023 | 28.76M |
| December 31, 2022 | 27.91M |
| September 30, 2022 | 25.76M |
| June 30, 2022 | 33.10M |
| March 31, 2022 | 25.17M |
| December 31, 2021 | 26.80M |
| September 30, 2021 | 27.26M |
| June 30, 2021 | 25.79M |
| March 31, 2021 | 20.03M |
| December 31, 2020 | 29.03M |
| September 30, 2020 | 17.67M |
| June 30, 2020 | 14.80M |
| March 31, 2020 | 14.57M |
| December 31, 2019 | 14.28M |
| September 30, 2019 | 15.93M |
| Date | Value |
|---|---|
| June 30, 2019 | 15.48M |
| March 31, 2019 | 12.56M |
| December 31, 2018 | 15.13M |
| September 30, 2018 | 12.86M |
| June 30, 2018 | 11.08M |
| March 31, 2018 | 11.12M |
| December 31, 2017 | 11.78M |
| September 30, 2017 | 10.45M |
| June 30, 2017 | 10.04M |
| March 31, 2017 | 9.628M |
| December 31, 2016 | 8.443M |
| September 30, 2016 | 11.58M |
| June 30, 2016 | 9.525M |
| March 31, 2016 | 8.265M |
| December 31, 2015 | 8.378M |
| September 30, 2015 | 6.866M |
| June 30, 2015 | 5.428M |
| March 31, 2015 | 3.736M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
14.28M
Minimum
Dec 2019
33.10M
Maximum
Jun 2022
23.32M
Average
25.46M
Median
Research and Development Expense (Quarterly) Benchmarks
| PDS Biotechnology Corp | 6.704M |
| PAVmed Inc | 1.941M |
| Moderna Inc | 1.063B |
| Altimmune Inc | 21.49M |
| iBio Inc | 0.904M |